 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The BSE stock has seen a breakout of falling resistance trendline adjoining March 15 last year (record high) and August 24 this year. The stock climbed over 6 percent to Rs 967.8 and formed long bullish candlestick pattern on the daily timeframe with above average volumes.

Trade Spotlight | Your strategy for Sterlite Technologies, BSE, Sun Pharma Advanced Research today

Sun Pharma Adv Standalone March 2023 Net Sales at Rs 47.69 crore, up 88.95% Y-o-Y

There has been a significant increase in clinical trial expenses, product development expenses, and professional charges during the last quarter of financial year 2022-23.

Sun Pharma Advanced Research Company falls 5% as quarterly loss widens to Rs 82 crore

Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 1220 in its research report dated January 31, 2023.

Buy Sun Pharma; target of Rs 1220: Motilal Oswal

SEZABY is the first and only product approved by the US Food and Drug Administration (USFDA) for the treatment of neonatal seizures in term and preterm infants, Sun Pharma said in a regulatory filing.

Sun Pharmaceutical launches phenobarbital sodium injection in US

Sun Pharma Advanced Research Company has allotted 4,77,87,627 equity shares on 06 January 2023 on conversion of equal number of warrants. Post allotment, the paid up equity share capital has increased to Rs.32,31,17,094 (32,31,17,094 equity shares of face value of Re.1 each fully paid up). Consequent to the above allotment, Shanghvi Finance (SFPL) has ceased to be the Companys Holding Company as its percentage shareholding along with its subsidiaries in the Company has reduced from 52.07% to 44.37%.The number of shares held by SFPL and its subsidiaries in the Company remain unchanged.

Sun Pharma Advanced Research Company allots 4.77 cr equity shares on conversion of warrants 

Poly Medicure rose 5 percent to Rs 952.5 and formed big bullish candlestick pattern on the daily charts with strong volumes. In fact, it has seen a breakout of downward sloping resistance trend line adjoining several points from the October high.

Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 1240 in its research report dated November 02, 2022.

Buy Sun Pharma; target of Rs 1240: Motilal Oswal

Sun Pharmaceutical’s foray into specialty drugs was in some ways driven by an existential threat posed by rising competition to its generic drug business in the US. In the September quarter, it reported sales of $200 million from specialty drugs in the US, up 27.5 percent YoY

Sun Pharma’s specialty drugs bet is beginning to pay off

The paper stocks were buzzing last week as we witnessed buying interest in some of the counters with good volumes. Satia Industries has seen a breakout from a long consolidation phase and has resumed its uptrend with a ‘Higher Top Higher Bottom’ structure

Top 10 trading ideas for November series as bulls gear up to charge again

Sun Pharma Advanced Research Co. Ltd. is a bio-pharmaceutical company, which engages in the research and development of pharmaceuticals. Its projects include new chemical entity research and novel drug delivery systems. The company was founded on March 1, 2006 and is headquartered in Mumbai, India.

Watchers	35
52-Wk Low	162.10
52-Wk High	265.85

Market Cap	73.86B
Volume (M)	265,538.00
52-Wk High	265.85
52-Wk Low	162.10

SPARC.NSE Sun Pharma Advanced Research Co. Ltd

About

Feed

News

Fundamentals